Information  X 
Enter a valid email address

Elsevier (REL)

  Print      Mail a friend       Annual reports

Monday 02 June, 2008

Elsevier

CrossFire Beilstein Expands Content With Multi-...





FRANKFURT, Germany, June 2 /PRNewswire/ --

    - New Multi-Step Reactions Enable More Efficient Synthesis Routes for 
Researchers


FRANKFURT, Germany, June 2 /PRNewswire/ --

    Elsevier Information Systems GmbH, a subsidiary of Elsevier, the leading
global publisher of scientific, technical and medical information, announced
today that from June 2008 CrossFire Beilstein will incorporate multi-step
reactions into its database. Multi-step reactions enable users to go beyond
fundamental reactions: they will be able to view and understand the
individual steps within the overall reaction scheme, as well as find suitable
starting points for their synthesis design.



    Designed specifically to address user expectations, the addition of
multi-step reactions in CrossFire Beilstein supports retro synthesis and
enables chemists to find and check better pathways and more effective
synthesis routes -- from simple, readily available starting materials to
their desired target molecule. In addition, a broader range of synthesis
routes is available to generate compound libraries in High Throughput
Screening. This finer granularity of the reaction data increases the
database's value to synthetic and organic chemists both in industry and
academia. CrossFire Beilstein's rich content also serves as the foundation
for the next generation of information tools that will further support the
selection, design and optimization of synthetic processes.



    The addition of multi-step reactions to CrossFire Beilstein's content has
been met with positive response from both the corporate and academic sectors.
"The importance of efficient synthetic routes and straightforward access to
relevant reaction data is paramount," says Graeme Robertson, Vice President,
Portfolio Management, Siena Biotech S.p.A., Italy, and Chairman of the
CrossFire Beilstein Database Advisory Board. He continues that "The enhanced
multi-step reactions content will enable chemists to find the best possible
routes available and better design the synthesis of target molecules, no
longer limited to single step reactions."



About CrossFire Beilstein

    The CrossFire Beilstein database (http://www.info.crossfirebeilstein.com)
is the world's largest compilation of chemical facts. As the cornerstone
database in organic chemistry, the CrossFire Beilstein database is essential
for generating new leads, planning synthetic routes (including starting
materials and intermediates), determining bioactivity and physical
properties, and ascertaining the environmental fates of compounds. Its
experimentally validated, reliable, high-quality data already sets CrossFire
Beilstein apart from other compound/reaction and bibliographic databases.



About Elsevier

    Elsevier is a world-leading publisher of scientific, technical and 
medical information products and services. Working in partnership with the 
global science and health communities, Elsevier's 7,000 employees in over 70 
offices worldwide publish more than 2,000 journals and 1,900 new books per 
year, in addition to offering a suite of innovative electronic products, such 
as ScienceDirect (http://www.sciencedirect.com/), MD Consult 
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.



    Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).



    
    Dr. Claudia Barzen,
    Phone: +49-69-5050-4246,
    E-mail: [email protected] .

a d v e r t i s e m e n t